JBM (Healthcare) (HKG:2161) recorded a 53% rise in attributable profit for the six months ended Sept. 30 to HK$95.9 million from HK$62.5 million in the year-ago period, a Tuesday filing with the Hong Kong bourse stated.
Earnings per share were HK$0.1163 in the fiscal first half, up from HK$0.0687 in the corresponding period of fiscal year 2023.
The Chinese medicine distributor's revenue rose by 22% to HK$399 million in the interim period from HK$326.8 million a year prior.
The firm declared an interim dividend of HK$0.055 per share for the half year, payable Jan. 15, 2025, to shareholders of record on Dec. 20, 2024.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments